Previous 10 | Next 10 |
home / stock / tkphf / tkphf news
Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...
Takeda Teams Up with ProThera on IAIP Therapy Takeda Pharmaceutical Company Limited ( TAK ) announced inking a new deal with ProThera Biologics for the purpose of developing IAIP therapy. This plasma-derived therapy is intended to be used for treating acute inflammatory conditions. Both th...
The European Commission has extended Takeda Pharmaceutical's ( OTCPK:TKPHF ) current marketing authorization of ALUNBRIG (brigatinib) to include use as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer...
Evotec SE ( OTCPK:EVOTF ) announces that Evotec GT has established a long-term research alliance with Takeda ( OTCPK:TKPHF ) to support latter's research-stage gene therapy discovery programs. More news on: Evotec SE, Takeda Pharmaceutical Company Limited, Evotec SE, Healthcare...
Quick Take Keros Therapeutics ( KROS ) intends to raise $75 million from the sale of its common stock, per an amended S-1/A regulatory filing . The company is advancing a pipeline of drug treatment candidates for hematological and musculoskeletal diseases. KROS is entering Phase 2 trial...
New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Bcl-2-Like Protein 1 Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to offer updates and...
Codexis (NASDAQ: CDXS ) has signed a strategic collaboration and license agreement with Takeda Pharmaceutical ( OTCPK:TKPHF ) for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor de...
Quick Take NLS Pharmaceutics ( NLSP ) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement . The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders. NLSP expects to begin...
Takeda Pharmaceutical's ( OTCPK:TKPHF ) Millennium units is suing Sun Pharmaceuticals Industries ( OTCPK:SMPQY ), alleging a generic version of its Ninlaro cancer treatment proposed by Sun Pharma infringes on three of its patents. More news on: Takeda Pharmaceutical Company Limited, Sun Ph...
Takeda Pharmaceutical ( OTCPK:TKPHF ) gets a positive CHMP opinion recommending approval of the subcutaneous form of vedolizumab biologic for maintenance therapy in adults with moderately to severely active ulcerative colitis or Crohn's disease. More news on: Takeda Pharmaceutical Compan...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Co Ltd Company Name:
TKPHF Stock Symbol:
OTCMKTS Market:
Takeda Pharmaceutical Co Ltd Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...